| 1 | |
|----------------------------|--|
| 2 | |
| 3 | |
| 4 | The role of veterinary diagnostic laboratories during COVID-19 |
| 5 | response in the United States |
| 6 | |
| 7 | Nia Clements ¹ , Diego G. Diel ² , François Elvinger ² , Gary Koretzky ³ , Julie Siler ¹ , and Lorin D. |
| 8 | Warnick ^{2*} |
| 9 | |
| 10 | |
| 11 | |
| 12 | |
| 13 | ¹ Department of Public and Ecosystem Health, Cornell University, Ithaca, NY, United States |
| 14 | ² Department of Population Medicine and Diagnostic Sciences, Cornell University, Ithaca, NY, |
| 15 | United States |
| 16 | ³ Department of Medicine, Weill Cornell Medicine, New York, NY United States and Department |
| 17 | of Microbiology and Immunology, Cornell University, Ithaca, NY |
| 18 19 20 21 22 | * Corresponding author |
| 23 | Email: ldw3@cornell.edu (LW) |
| 24 25 26 | |

27 Abstract

28 Robust testing capacity was necessary for public health agencies to respond to severe acute 29 respiratory syndrome coronavirus 2 (SARS-CoV-2) during the coronavirus disease 19 (COVID-30 19) pandemic. As the nation faced the need for robust testing capacity, it became necessary to use 31 all possible resources. In many cases, veterinary diagnostic laboratories rose to meet this demand 32 because these facilities routinely perform high throughput diagnostic testing of large animal 33 populations and are typically familiar with pathogens of high pandemic concern. In this study, we 34 evaluated the impact of veterinary diagnostic laboratories in the United States on SARS-CoV-2 35 testing. Results of surveys, semi-structured interviews, and analysis of publicly available 36 information showed that veterinary diagnostic laboratories had a substantial impact on human 37 health through population-level testing in the COVID-19 response, supporting timely and 38 informed public health interventions. This success was not without significant hurdles, as many 39 participating veterinary diagnostic laboratories experienced restriction in their response due to 40 difficulties obtaining the Clinical Laboratory Improvement Amendments (CLIA) certification 41 required to conduct human diagnostic testing. Our results point out the importance of reducing 42 hurdles before the next major public health emergency to enhance access to testing resources 43 overall and to ultimately improve population health.

44 Introduction

45 Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was first detected in Wuhan,
46 Hubei Province, China when numerous cases of atypical pneumonia linked to the Hunan Seafood
47 Market emerged in December of 2019.[1,2] Soon after the initial cases in China, SARS-CoV-2
48 was detected and reported in the United States (US) on January 21, 2020 in Washington State in a

49 patient with respiratory illness.[2] This case was determined to be epidemiologically linked to 50 Wuhan, China.[2] As clinical case numbers mounted, a public health emergency was declared 10 51 days later on January 31 by the United States Department of Health and Human Services.[2] By 52 this time, the disease was rapidly spreading worldwide, triggering mass shutdowns to protect 53 public health while key characteristics of the disease remained unknown.

54 The need for robust SARS-CoV-2 testing was apparent from the pandemic's start. When the 55 outbreak was in its early stages, testing was concentrated in US major ports of entry to mitigate 56 travel-related spread.[2] The need to expand testing became urgent with evidence for local spread. 57 Additionally, key epidemiological characteristics of the virus were revealed, such as SARS-CoV-58 2's early basic reproduction number between 2.2 and 2.7[3] and the high incidence of 59 asymptomatic disease and efficient virus transmission.[1] The emergence of non-travel related 60 cases, coupled with the epidemiological characteristics of SARS-CoV-2, sounded an alarm to the 61 highly infectious nature of the virus and made it clear that broad and aggressive testing would be 62 required to control virus spread. Public health messaging emphasized this point, communicating 63 that testing was necessary to "flatten the epidemic curve," referring to a strategy of reducing the 64 number of new disease cases by using public health interventions, including testing, so that those 65 infected would be aware and take appropriate measures to prevent viral transmission.[4,5]

66 Countries that incorporated a rigorous testing approach as part of their strategy to "flatten the 67 curve" experienced relative success in controlling and decreasing the spread of the virus. For 68 example, with a population of 51.8 million,[6] South Korea achieved a SARS-CoV-2 testing 69 capacity of 15,000 tests per day early in the pandemic.[4] High testing capacity was achieved 70 through accessible drive-through and walk-in testing sites, allowing for a testing rate of 17,000 71 tests per million people by June 2020.[4] This robust testing approach was a factor among other

strategies (e.g. extensive contact tracing, rigid quarantine rules)[7] that prevented the need for lockdowns. South Korea's public health solution to SARS-CoV-2 consequently had numerous positive downstream effects, such as maintenance of livelihoods in communities and diminishing economic disruption.[4] Given South Korea's SARS-CoV-2 outcomes, it is clear that effective control was achievable, emphasizing the importance of high testing capacity, among other strategies, in this emergency response.

78 One approach to achieve high testing capacity is through the collaboration of human diagnostic 79 laboratories and veterinary diagnostic laboratories. As stated by the World Organization for 80 Animal Health, veterinary diagnostic laboratories are well suited to supporting testing responses 81 in public health emergencies "because they have experience in quality assurance, biosafety and 82 biosecurity, and high throughput testing for the surveillance and control of infectious diseases in 83 animals, some of which are zoonotic."[8] Importantly for quality control, veterinary diagnostic 84 laboratories, like human health laboratories, have external accreditors that ensure testing is performed under guidelines that promote accuracy and workforce competence[9] and have 85 86 Biological Safety Level 2 and 3 facilities to handle diseases of public and animal health 87 concern.[10]

In the throes of a public health crisis due to zoonotic infection, veterinary and animal diagnostic laboratories have qualities that may make them more nimble than human health laboratories. For instance, veterinary diagnostic laboratories strive to develop novel testing programs given their familiarity with a wide range of pathogens that have zoonotic potential.[11] Furthermore, animal laboratories have extensive experience in surveilling livestock and poultry for highly pathogenic diseases as threats emerge.[12] Because veterinary diagnostic facilities surveille entire populations of animals to protect the agriculture industry, these laboratories are designed to conduct "herd"

95 testing, whereas human diagnostic laboratories focus on testing individuals. This testing capacity 96 of veterinary laboratories provides a unique opportunity to enable entire populations of humans to 97 be tested in the face of health threats like SARS-CoV-2. Given these characteristics, a 98 collaboration between human health and veterinary diagnostic laboratories can synergize to 99 develop testing programs during pandemics.

100 This potential for collaboration between human diagnostic laboratories and animal diagnostic 101 laboratories is already recognized from a regulatory standpoint, as human-focused diagnostic 102 initiatives can be housed in veterinary diagnostic laboratories with Clinical Laboratory 103 Improvement Amendments (CLIA) certification by the Centers for Medicare and Medicaid 104 Services.[13] For instance, CLIA enabled seven of the sixty member laboratories of the National 105 Animal Health Laboratory Network which is coordinated by the USDA Animal and Plant Health 106 Inspection Service to be certified for human SARS-CoV-2 samples by June 2020, early in the 107 pandemic.[14]

The objective of this study was to determine the extent and quantify the impact of SARS-CoV-2 testing in veterinary diagnostic laboratories to better understand their role in the SARS-CoV-2 response, and to inform decisions for future public health emergencies among veterinary laboratories, human health organizations, and regulatory bodies such as the Centers for Medicare and Medicaid Services.

113 Materials and methods

- 114 Survey of veterinary diagnostic laboratories
- 115 Source population

Following formal survey approval by the American Association of Veterinary Medical Colleges, an online cross-sectional Qualtrics survey was distributed to American Association of Veterinary Medical Colleges and the National Animal Health Laboratory Network member laboratories in the United States using email listservs. If publicly available information detailed that a laboratory had a robust SARS-CoV-2 testing program but no response was recorded for this laboratory following the survey's due date, laboratory leadership were contacted directly via email to personally invite them to participate. Responses were collected between March 31, 2023 and July 18, 2023.

123 Survey

124 Respondents first identified the name of their laboratory and whether they conducted animal 125 SARS-CoV-2 diagnostic testing and human SARS-CoV-2 testing. Respondents who conducted 126 animal SARS-CoV-2 testing were asked 6 questions about the duration of the testing program, 127 number of animals tested, testing methodology, and if viral nucleic acid sequencing was 128 conducted. Respondents whose laboratories conducted human SARS-CoV-2 testing were asked 129 19 questions across 4 domains, including test characteristics, timeline and testing volumes, testing 130 logistics, and reflections on emergency response. For all questions respondents could either select 131 from an array of response choices or write in a response. At the end of the survey, respondents had 132 the option to include their contact information for follow-up. A copy of the survey may be found 133 in the supporting information (see S1 File).

134 Survey analysis

Responses were analyzed by descriptive statistics and qualitative analysis using Microsoft Excel and R (version 2022.07.2+576 "Spotted Wakerobin"). R packages included readr, questionr, and ggplot2. When curating data for analysis, duplicate laboratory responses were combined into one entry. In the case of numerical response entry (e.g., date of testing commencement, number of total

139 samples tested), the numerical response that was either the most detailed (e.g., August 21, 2023 140 versus August 2023) or the largest (e.g., 1,245 samples versus 1,000 samples) was used in the final 141 response for laboratories with duplicate responses. Incomplete responses that either could not be 142 traced back to a specific institution or had no meaningful information (e.g., most questions 143 unanswered) were removed from the dataset.

144 Semi-structured interviews with survey respondents

145 **Source population**

146 To learn more about the specific elements of a laboratory's response, a convenience sample of 147 survey respondents were asked to participate in a semi-structured interview. Two groups of 148 interviewees were invited: (1) laboratories that conducted human SARS-CoV-2 testing and (2) 149 laboratories that did not conduct human SARS-CoV-2 testing. For the first group, invitations for 150 interview were sent to two survey respondents per region of the US (Northeast, South, Midwest, 151 and West) to include laboratories representing all US regions. Within regions, invitations for 152 interview were selected based on interesting elements of a laboratory's response (e.g., unusually 153 high testing capacity, testing methodology that differed from what was observed in most 154 responses). Based on the barriers cited by these interview respondents in group 1, laboratories in 155 group 2 were invited for interview to gain a deeper understanding of what barriers may exist in 156 conducting human SARS-CoV-2 testing. One laboratory that did not conduct human SARS-CoV-2 157 testing per US geographic region was invited to interview, except for the Midwest because all 158 laboratories that responded to the survey in this region conducted human SARS-CoV-2 testing. 159 Across both group 1 and group 2, eleven interview invitations were sent and ten interviews were 160 conducted. One invited laboratory did not respond to requests for interview.

161 Interviews

162 Interviews lasted approximately 30 minutes and were conducted virtually via Zoom, Microsoft 163 Teams, or by phone. Interviewees were asked about what elements of their testing program were 164 most impactful on their laboratory's testing capacity, what barriers they experienced in either 165 setting up or operating their testing programs beyond those discussed in the survey responses, and 166 what information they would find useful for their current and future laboratory operations from 167 this publication. If time permitted, interviewees were asked for their major learning outcomes and 168 anticipated changes to pandemic preparedness following their experiences with SARS-CoV-2. For 169 interviewees whose institutions did not conduct SARS-CoV-2 testing, additional questions were 170 asked about their laboratory's regular operations and if there was consideration of using veterinary 171 laboratory resources during their institution's COVID-19 response. A copy of interview questions 172 may be found in the supporting information (see S2 File).

173 Interview analysis

During all but one interview, two researchers were present for interview facilitation and note taking. Information revealed during interviews that provided further insight into specific components of a survey response were included in the results section of this study. Themes consistent across most interviews were used to inform the discussion section of this manuscript.

178 **Evaluation of publicly available information**

To consider experiences of laboratories who conducted SARS-CoV-2 testing but did not participate in this study, public information was gathered to contextualize or provide further insight for survey and interview results. Publicly available information used for this analysis included peer-reviewed publications, online local or national news articles, white papers, and articles published by campus news. Google, Google Scholar, and the EBSCO database were used in these searches. Sample search terms included: ("SARS-CoV-2" OR "COVID19" OR "COVID-19")

AND ("veterinary diagnostic" OR "animal diagnostic" OR "veterinary lab" OR "animal lab") AND ("university" OR "college" OR "school"). In some cases, when gathering information for specific laboratories, the name of the institution of interest was included in the search terms. Information gathered from these searches supplemented information presented in surveys or interviews.

190 **Results**

In total, 76 invitations for participation were sent and 38 total responses were recorded, yielding a response rate of 50%. All regions of the US were accounted for by respondents, with most responding laboratories located in the Midwest and South (Fig 1). Thirty-three total states were represented (Fig 1).

195

Fig 1. Map of Survey Respondents. Light blue represents one responding laboratory and dark
blue represents two responding laboratories. Visualization made using Datawrapper.

198

Thirty (79%) of 38 responding veterinary diagnostic laboratories were operated within a university, of which 19 were operated within a college of veterinary medicine (Table 1). Eight laboratories (21%) were not affiliated with a college or university (Table 1). Of the 38 survey respondents, 20 (53%) conducted both animal and human SARS-CoV-2 testing, 7 conducted only animal testing, 4 conducted only human testing and 7 did not conduct human or animal tests (Table 1). More respondents conducted only animal testing than only human SARS-CoV-2 testing (7 laboratories versus 4 laboratories, respectively; Table 1).

206

207 Table 1. Organizational Structure and Distribution of Animal and Human SARS-CoV-2

208 Testing Among Responding Laboratories (n=38).

| Organizational structure of laboratory | Number of laboratories (%) |
|--|----------------------------|
| Operating within a college of veterinary medicine, partially/fully | state funded 6 (16) |
| Operating within a college of veterinary medicine, not state fund | led |
| | 13 (34) |
| Operating within a university, but not a college of veterina | ry medicine, $5(13)$ |
| partially/fully state funded | |
| Operated within a university, but not a college of veterinary m | nedicine, not $6(16)$ |
| state funded | |
| Not within a university or college of veterinary medicine, state f | unded 7 (18) |
| Not within a university or college of veterinary medicine, federa | lly funded 1 (3) |
| Testing conducted | |
| Conducted both animal and human SARS-CoV-2 testing | 20 (53) |
| Conducted animal SARS-CoV-2 testing but not human SARS-C | oV-2 testing 7 (18) |
| Conducted human SARS-CoV-2 testing but not animal SARS-C | oV-2 testing $4(11)$ |
| Did not conduct animal or human SARS-CoV-2 testing | 7 (18) |

209

210 Animal SARS-CoV-2 testing

- 211 Most laboratories that conducted animal SARS-CoV-2 testing began testing in early 2020 (58%),
- 212 followed by mid-2020 (29%) and late 2020 (13%; n = 24). Furthermore, 23 (88%) surveyed
- 213 laboratories were continuing to test animals as of May 2023 (n = 26).
- 214 The species of tested animals can be broadly categorized as wildlife (e.g., moose, bobcat),
- 215 companion animals (e.g., cats, dogs), agricultural or farming animals (e.g., cattle, pigs), and zoo
- 216 animals (e.g., tigers, lions). Among survey respondents, the animal category most tested was
- 217 companion animals (42%), followed by wildlife and zoo animals (23% respectively; Fig 2). Farm
- animals were the least tested animal category (13%; Fig 2). These results are consistent with the
- 219 United States Department of Agriculture reporting that companion animals were the main species
- tested, followed by wildlife and zoo animals.[15]

222 Fig 2. Frequency Distribution for Laboratories Testing Various Animal Species for SARS-

CoV-2 Among Survey Respondents. Animal species were categorized into companion, farm,
wildlife, and zoo animals and the bars represent the number of laboratories that tested for each
category.

226

227 The number of animal samples tested for SARS-CoV-2 among 22 survey respondents who 228 provided these numbers ranged from 9 to 3,600 animals, although this large range may be 229 accounted for by some survey respondents including research tests in addition to clinical or 230 diagnostic tests. Furthermore, it is possible that survey respondents reported the number of SARS-231 CoV-2 tests performed as opposed to the number of animals tested as some animals were tested 232 serially. Every laboratory that conducted animal SARS-CoV-2 testing used reverse transcription 233 polymerase chain reaction (RT-PCR) methodology for tests. In addition to RT-PCR testing, seven 234 respondents (29%) performed viral nucleic acid sequencing to gather genotypic information about 235 the viral variants.

236 Human SARS-CoV-2 testing

Of the 38 laboratories providing survey responses, 24 laboratories (63%) indicated that they conducted human SARS-CoV-2 testing. Among these 24 laboratories, 14 (58%) conducted human SARS-CoV-2 testing for a university population and 7 (29%) tested for the general community. Three laboratories tested for both a university population and the general community (13% respectively). Two laboratories conducted testing for local hospitals (8%). Fourteen of the 17 universities whose laboratories conducted testing for their populations had testing requirements that ranged from compulsory testing among specific student populations or under certain

conditions (e.g., student athletes, symptomatic individuals only) to the entire population (e.g.
students, faculty and staff) requiring testing.

246 The most common reason for human sample testing was to increase university testing capacity (17

247 laboratories; 71%), followed by increasing testing capacity for the local community (6

laboratories; 25%) and testing to decrease turnaround time (5 laboratories; 21%). Furthermore, 4

laboratories tested to increase testing capacity for the local health departments and hospitals (17%)

250 or to provide information to local health departments through sequencing (4 laboratories, 17%).

251 Research and reducing test cost were also cited as a testing motivation.

As was the case for animal tests, real-time RT-PCR was the most common method of SARS-CoV-2 testing and used in 22 (92%) laboratories. In addition to RT-PCR, laboratories also conducted enzyme-linked immunosorbent assays and sequencing. Most real-time RT-PCR tests targeted ORF1ab, spike, and nucleocapsid genes. As displayed in Fig 3, nasopharyngeal swabs were the most common sample type (14 laboratories; 58%) followed by anterior nares swabs (12 laboratories; 50%) and saliva (10 laboratories; 42%). Only one institution collected samples from nasal mid-turbinate swabs (4%) and oropharyngeal swabs (4%).

259

Fig 3. Frequency Distribution of the Sample Types Tested for SARS-CoV-2 Among the 24 Laboratories Surveyed That Conducted Human Testing.

262

263 Only 1 institution of the 24 that conducted human SARS-CoV-2 testing was responsible for sample 264 collection. At this institution, observed self-collection sampling occurred at designated campus 265 testing sites. Furthermore, one institution pooled diagnostic test samples and two laboratories 266 pooled surveillance tests. At the institution that pooled diagnostic tests, samples were pooled in

267 groups of five. When pools were positive, individual samples were tested separately following 268 deconvolution of the pools. Seventeen (74%) laboratories that tested human samples used 269 automation or robotics to achieve their testing capacity with the Kingfisher Flex most frequently 270 cited for high-throughput nucleic acid extraction. For human SARS-CoV-2 testing, 9 (39%) 271 institutions conducted viral nucleic acid sequencing to gather genotypic information about the viral 272 variants. Two of the fourteen laboratories that did not conduct viral nucleic acid sequencing sent 273 samples to state collaborators for sequencing. 274 Most laboratories began their human SARS-CoV-2 testing program in the late summer months of 275 2020. Most of these laboratories ended their testing programs mid-way through 2022, though one 276 ended as early as July 2020 and one was continuing testing until May 2023. 277 Maximum samples tested per day and total samples tested among the human SARS-CoV-2 testing 278 laboratories varied greatly across laboratories (Table 2). Across all laboratories, daily testing 279 capacity ranged from 300 to 14,000 samples tested per day, with a median of 2,000 samples per 280 day. The total number of samples tested ranged from 6,215 to 3,000,000 total samples, with a 281 median number of total samples tested of 121,546. There was no statistically significant 282 relationship between samples tested per day and result turnaround time (Spearman correlation 283 coefficient: -0.06; p = 0.789 > 0.05).

284

Table 2. Summary Statistics of Daily Testing Capacity and Total Samples Tested Among Laboratories That Conducted Human SARS-CoV-2 Testing, Stratified by Laboratories that

287 Used Robotics Versus Did Not Use Robotics (n = 24).

| | Minimum | Median | Maximum |
|---------------------------------|---------|--------|---------|
| Sample testing capacity per day | | | |
| Using robotics | 518 | 2,000 | 14,000 |
| Not using robotics | 300 | 600 | 5,823 |

| Total samples tested | | | |
|----------------------|-------|---------|-----------|
| Using robotics | 6,215 | 472,635 | 3,000,000 |
| Not using robotics | 8,500 | 43,498 | 850,000 |

288

289 Automation and Pooling

Laboratories using robotics tested more samples per day and tested more samples total than laboratories that did not use robotics (Table 2). The median number of samples tested per day was 2,000 for laboratories that used robotics and 600 for laboratories that did not use robotics (Table 2). Similarly, the median total number of samples tested for laboratories that used robotics was 472,635 samples versus a median number of samples of 43,498 samples for laboratories that did not use robotics (Table 2).

296 While automation was used for laboratories that had higher testing capacities, automation was not 297 essential to achieving a high testing capacity. One laboratory reported a daily testing capacity of 298 5,823 samples tested per day without use of robotics, which is substantially higher than the median 299 daily testing capacity of 600 samples tested per day among the non-automated group. This 300 laboratory achieved this high sample testing capacity by having a large workforce totaling 301 approximately 90 full time equivalents. The laboratory tested one-third of the student body each 302 week such that the entire study body was evaluated every three weeks, enabling the university to 303 detect and address hotspots of SARS-CoV-2 cases earlier and ultimately reduce the burden of 304 SARS-CoV-2 on campus.

One laboratory conducted pooling for diagnostic SARS-CoV-2 tests and, using this methodology, achieved a sample testing capacity of greater than 10,000 samples per day. Pooling was conducted in 96-welled plates, each containing 93 pools of 5 samples. Processed samples were placed into barcode-visible Biomek tube racks so that Biomek i5 could generate pools while also allowing the Data Acquisition and Reporting Tool 2.0 software to record the position of each sample in the

310 pooled wells. The well position within the 96-well plate and the sample position in storage racks 311 were retained and managed through a custom software application (COVID-19 Receiving 312 App).[16] Three wells were left as controls.[16] In forty-five minutes, 465 samples were pooled 313 into 93 wells of the 96-well plate.[16] If any pools tested positive, deconvolution took place and 314 samples were tested individually.[16] Result reporting for pooled samples had a median turn-315 around time of 4 hours and 46 minutes, although positive pools had a median turn-around time of 316 22 hours and 19 minutes.[16] Samples that were not pooled (and tested individually) had a median 317 turn-around time of 3 hours and 56 minutes.[16] Although logistically more complicated, pooling 318 increased efficiency, enabling rapid test result communication, which ultimately improved the 319 effectiveness of intervention among positive cases. Pooled testing also resulted in lower cost per 320 sample tested due to lower workforce requirements and conservation of testing reagents and 321 supplies.

Pooling, however, was not required to achieving a high sample testing capacity. The laboratory with the highest number of samples tested of all surveyed laboratories, with a daily sample testing capacity of 14,000 samples tested and 3,000,000 samples tested overall, did *not* pool samples for testing. This strategy, however, involved a large number of full time FTE's and extended/double shifts.

While some laboratories did consider pooling, one barrier to using pooling in the diagnostic workflow included lack of access to the proper equipment to conduct pooling effectively. One laboratory noted that the use of saliva samples and the lack of access to liquid sensing tips caused the sample to dribble throughout the machine during pooling trials. Given the low population size on this institution's campus during the pandemic, they decided to focus on testing optimization in other areas of the testing scheme instead of pooling. A different laboratory noted that pooling was

not pursued because the deconvolution of positive samples would have increased testing cost and sample result turnaround times. Given these barriers, the decision to pool as a mechanism of increasing testing capacity was dependent on resources, such as workforce, lab supplies, and budget.

337 **Barriers to testing**

338 Seventeen (71%) laboratories reported that obtaining the proper certification or licensure was an 339 initial impediment to testing human SARS-CoV-2 samples (Table 3). The Clinical Laboratory 340 Improvement Amendments (CLIA) certification was the most frequently cited barrier related to 341 licensure for testing. Limited human workforce capacity and having other organizational 342 responsibilities were also primary barriers to testing human samples (58% and 38% respectively; 343 Table 3). Three laboratories cited lack of qualified workforce and the need for constant staff 344 training to ensure consistent results as additional issues. These same laboratories also indicated 345 that managing work schedules to ensure testing capacity while preventing burn out among 346 employees was challenging. One institution stated that tripling the size of their workforce in one 347 month to accomplish SARS-CoV-2 testing was easy, as graduate students, professors, and 348 department heads took pride in volunteering for the testing initiative. Given that normal operations 349 were interrupted, many students and faculty had more time to dedicate towards a testing initiative, 350 requiring this institution to limit the number of volunteers working in the diagnostic laboratory. 351 Limited physical space for testing and obtaining funding were the least frequently reported barriers 352 to human testing (21% and 17% respectively), and none of the surveyed laboratories reported 353 achieving satisfactory testing accuracy as a barrier to testing operations (Table 3). 354 One frequently cited barrier to SARS-CoV-2 testing was institutional leadership. Four laboratories

354 One frequentry energy of the SARS-CoV-2 testing was institutional readership. Four laboratories
 355 noted that university administration constrained SARS-CoV-2 testing initiatives. In one case,

administration viewed SARS-CoV-2 as not sufficiently urgent to warrant resources to mount a testing response. For this academic institution—and another institution that cited internal leadership problems as a barrier to operation—there was an additional concern that reporting SARS-CoV-2 numbers on campus would result in diminished enrollment in the universities. To justify the need for SARS-CoV-2 testing despite these concerns, one institution reported that resources were allotted to testing once a county public health agency became involved to advocate for the importance of a testing program.

363 Support by human health agencies (e.g., public health agencies, human health providers) for 364 veterinary diagnostic laboratories to participate in SARS-CoV-2 response was not universal, as 365 two laboratories cited human health agencies as a barrier to developing a testing program. One 366 institution described how public health groups made the state's granting of CLIA certification 367 difficult for the veterinary diagnostic laboratory. In this case, the institution reported that these 368 human health agencies eventually realized the positive impact that the veterinary laboratories 369 could have on achieving the testing capacity required to control the pandemic. Consequently, the 370 veterinary diagnostic laboratory began surveillance testing, resulting in a surge of the state's 371 SARS-CoV-2 positivity rate, and then consequently the granting of CLIA licensure for the 372 laboratory to begin diagnostic testing. While this ultimate approval for diagnostic testing enabled 373 a higher testing capacity to be achieved in this state, this response was delayed.

374

375 Table 3. Cited Barriers to Human SARS-CoV-2 Testing Operations Among Respondents (n

376 = **24**).

| Barrier | Frequency (%) |
|--|---------------|
| Obtaining the proper certifications and/or licensure | 17 (71) |
| Limited human workforce capacity | 14 (58) |
| Other organizational responsibilities | 9 (38) |

| Limited testing equipment, materials, and supplies | 8 (33) |
|---|--------|
| Other (e.g., billing insurance, IT issues, state or local leadership) | 8 (33) |
| Difficulty coordinating with other organizations | 7 (29) |
| Limited physical space for testing | 5 (21) |
| Obtaining funding | 4 (17) |
| Achieving satisfactory test accuracy | 0 (0) |

377

378 **Discussion**

379 Many veterinary diagnostic laboratories developed successful programs for testing human samples 380 for SARS-CoV-2, applying high throughput and high complexity diagnostic principles used in 381 their routine testing operations. A total of 8,273,602 human samples were tested by surveyed 382 laboratories participating in this study. One university's veterinary diagnostic laboratory tested 383 one-third of their university students each week to ensure that every student was tested every three 384 weeks, allowing for the identification of outbreak clusters on campus and timely intervention by 385 public health groups. Another university, early in the pandemic, determined that the student body 386 would need to be tested twice per week to allow faculty, staff and students to safely return to work 387 and school, requiring a testing capacity of 7,000 samples tested per day.[17,18] This animal 388 diagnostic laboratory, using its expertise and population testing principles and workflows 389 established a final daily testing capacity exceeding 10,000 samples with a result turnaround time 390 of 24 to 36 hours, ultimately testing 2,079,685 samples in a rural region where closure of the 391 university would have had large impacts on accessibility of testing for local community members. 392 Some veterinary diagnostic laboratories offered testing services to nearby institutions and satellite 393 campuses and consequently, some of these university testing programs, with their animal 394 population based high throughput design, made up a large proportion of total state tests. One 395 laboratory's testing capacity of 18,000 samples daily corresponded to 20% of all daily testing

396 completed in that state, and to 1.5-2.5% of all SARS-CoV-2 daily samples tested nationwide.[19]
397 One other veterinary diagnostic laboratory conducted 25% of its state's total tests; In fact, this
398 laboratory tested four times as many SARS-CoV-2 samples than the state's public health
399 laboratories[12] and more than any other laboratory in the state. Given these contributions,
400 veterinary diagnostic laboratories have demonstrated their importance and positive impact in
401 achieving high testing capacity on population-wide scale during public health emergencies.

These contributions to states' large scale testing programs were achieved despite significant challenges, with the most frequently cited obstacle being the regulatory requirements that prevented veterinary diagnostic laboratories from participating either early in the pandemic or, depending on states' interpretation of rules and regulations, throughout the pandemic.

406 There were two testing options for SARS-CoV-2 laboratories: surveillance testing and diagnostic 407 testing. The Food and Drug Administration authorized surveillance testing for emergency use 408 during the SARS-CoV-2 pandemic, allowing laboratories-including veterinary diagnostic 409 laboratories—to monitor SARS-CoV-2 incidence in populations.[20] Surveillance testing, 410 however, does not permit contact tracing of detected cases (i.e. tracing back results to tested 411 individuals and determining potential infected and infectious contacts), thereby decreasing the 412 public health usefulness of surveillance testing programs. [20] To conduct diagnostic testing which 413 allows identification of the infected patient and subsequent contact tracing, laboratories must 414 obtain Clinical Laboratory Improvement Amendments (CLIA) certification with requirements that 415 were difficult, or depending on states' interpretation, impossible to meet for veterinary diagnostic 416 laboratories. The requirement in 42 CFR §493.1443 in particular states that a laboratory director 417 must be a licensed medical professionals (i.e., Doctor of Osteopathic Medicine, Medical Doctor, 418 Doctor of Veterinary Medicine) with training and professional experience limited to human or

419 public health diagnostic testing, specifically that "[1]aboratory testing of non-human specimens is 420 not acceptable experience, e.g., environmental, animal testing."[21] This requirement prevented 421 some veterinary diagnostic laboratories from participating at all despite their expertise, experience 422 and capacity in testing more samples with "the same machinery, scientific theory, and tests as 423 human health facilities with the only difference being the taxonomy of the sample source."[12] A 424 case in point was that veterinary laboratory diagnosticians in one state were called upon to train 425 human health professionals to perform the testing that they themselves were not certified to 426 perform and participate in the SARS-CoV-2 testing response. Clinical Laboratory Improvement 427 Amendments (CLIA) certification thus constituted a "bureaucratic wall" in many states, requiring 428 the establishment of sometimes complex partnerships of veterinary diagnostic laboratories with 429 state or private human health partners.[22] Two interviewed laboratories obtained rapid and 430 independent certification, due to support within established networks in their State Department of 431 Health, or due to state legislators' support, as well as strong advocacy by university leadership.

432 Most animal diagnostic laboratories, however, faced significant barriers in obtaining CLIA 433 certification due to challenges in contracting with a human health partner and strict state 434 interpretations of CLIA requirements. Differences in CLIA enforcement state-to-state certainly 435 contributed to inequities in testing resources across the country. Attitude towards diagnostic testing 436 by veterinary laboratory also constituted an obstacle in some states, despite veterinary and human 437 diagnostic laboratories using the same diagnostic methods. In fact, restrictions on one veterinary 438 diagnostic laboratory to only provide surveillance testing with confirmation of positive findings at 439 the public health laboratory were lifted within days of program commencement, resulting in lifted 440 restrictions only once the public health laboratory could not cope with the testing demand.

441 There is an urgent need when preparing for public health emergencies to reduce barriers and 442 consider available high quality testing capacity in veterinary diagnostic laboratories. Veterinary 443 diagnostic laboratories, often located in rural areas, can have a significant impact on increasing 444 accessibility to testing among rural residents. For example, the state of Washington had fifteen 445 operating SARS-CoV-2 testing laboratories. Fourteen of these laboratories were in the state's 446 Western region, with the one animal diagnostic laboratory in the East filling an important gap in 447 accessibility to testing. 448 Despite the important role that veterinary diagnostic laboratories played in the pandemic response,

there is insufficient support from non-animal health institutions, ultimately impeding animaldiagnostic laboratory's abilities to achieve CLIA certifications. One interviewee noted:

451 *"We, diagnostic veterinary labs, continue to see push back from public health laboratories.*452 *The way we function, the qualifications, are equivalent to CLIA lab directors but because*

453 of legislation we can't just jump in and do certain things. The best outcome at a national

454 *level to this effort and for preparedness for the future would be for vet labs to be at least*

455 *permitted on a stand-by basis to jump in without hurdles from CLIA.*"

This interviewee also describes how the "nation is losing out on capacity by excluding the
possibility that in an emergency basis, that [animal diagnostic laboratories] could jump in and get
going." The SARS-CoV-2 pandemic helped convey the impact that veterinary animal
laboratories may have in population health emergencies despite the presence of significant
barriers, indicating a need for change.

461 Unfortunately, despite this need for change, on July 26, 2022, the Centers of Medicare &

462 Medicaid Services (CMS) proposed revisions to CLIA in the *Federal Register, Vol.* 87, No. 142

| 463 | stating that they "believe that DVM should be removed from the qualifying doctoral degrees as it |
|-----|---|
| 464 | is not relevant to testing on specimens derived from the human body" despite "CMS |
| 465 | recogniz[ing] that the COVID-19 public health emergency (PHE) requires flexibility, and [they |
| 466 | are] are committed to taking critical steps to ensure America's clinical laboratories can respond |
| 467 | during a PHE to provide reliable testing while ensuring patient health and safety." [9] The |
| 468 | American Association of Veterinary Laboratory Diagnosticians responded to this proposed |
| 469 | revision by stating[9]: |

- 470 *"The incorporation of [testing by veterinary diagnostic laboratories] into the [COVID-*
- 471 *19 public health emergency] response was often significantly delayed due to the*
- 472 *inflexibility regarding recognition of [veterinary diagnostic laboratory] staff's training,*
- 473 knowledge and experience as being sufficiently equal to that mandated under CLIA. It is
- 474 *paradoxical that on the heels of the strong participation [of veterinary diagnostic*
- 475 *institutes] in the COVID-19 [public health emergency], the new proposal actually seeks*
- 476 to further restrict any recognition of veterinary training and degrees as being germane to
- 477 *the oversight of diagnostic testing of human samples.*"
- 478 Given the undeniable and positive impact of veterinary diagnostic laboratory participation in the
- 479 COVID-19 response, policymakers and regulators should focus on reducing regulatory
- 480 impediments to enhance the Nation's preparedness and emergency response capacity.

481 **Conclusion**

- 482 Veterinary diagnostic laboratories were major contributors to the Nation's COVID-19 pandemic
- 483 public health response by adding to local and regional SARS-CoV-2 testing capacity and

| 484 | ass | isting in "flattening the epidemic curve." It is imperative that human health agencies and |
|-----|------|---|
| 485 | fed | eral regulators recognize these contributions and readily collaborate with and call on the |
| 486 | exp | pertise and resources of the veterinary community and diagnostic centers as new public health |
| 487 | thre | eats emerge. More than 60% of human infectious diseases have a zoonotic origin, which |
| 488 | unc | lerscores the urgent need to promote animal and human diagnostic collaboration under the |
| 489 | On | e Health umbrella in preparation for future pandemics.[23] |
| 490 | R | eferences |
| 491 | 1. | Chams N, Chams S, Badran R, Shams A, Araji A, Raad M, et al. COVID-19: A |
| 492 | | Multidisciplinary Review. Front Public Health [Internet]. 2020 [cited 2023 Feb 27];8. |
| 493 | | Available from: https://www.frontiersin.org/articles/10.3389/fpubh.2020.00383 |
| 494 | 2. | Patel A. Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel |
| 495 | | Coronavirus Outbreak — United States, December 31, 2019–February 4, 2020. MMWR |
| 496 | | Morb Mortal Wkly Rep [Internet]. 2020 [cited 2023 Feb 27];69. Available from: |
| 497 | | https://www.cdc.gov/mmwr/volumes/69/wr/mm6905e1.htm |
| 498 | 3. | Sanche S, Lin YT, Xu C, Romero-Severson E, Hengartner N, Ke R. High Contagiousness |
| 499 | | and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2 - Volume 26, |
| 500 | | Number 7—July 2020 - Emerging Infectious Diseases journal - CDC. [cited 2023 Mar 8]; |
| 501 | | Available from: https://wwwnc.cdc.gov/eid/article/26/7/20-0282_article |
| 502 | 4. | Fenemigho I, Ukponmwan E, Nnakwue EC, Udoete I, Asuzu C, Adaralegbe A, et al. |
| 503 | | COVID-19, flattening the curve: recommendations towards control and managing a second |
| 504 | | wave. J Glob Health Rep. 2020 Aug 10;4:e2020074. |

| 505 | 5. | New COVID-19 Cases Worldwide [Internet]. Johns Hopkins Coronavirus Resource Center. |
|-----|-----|--|
| 506 | | [cited 2023 Mar 8]. Available from: https://coronavirus.jhu.edu/data/new-cases |
| 507 | 6. | Population, total - Korea, Rep. Data [Internet]. The World Bank. [cited 2023 Mar 15]. |
| 508 | | Available from: |
| 509 | | https://data.worldbank.org/indicator/SP.POP.TOTL?end=2021&locations=KR&start=1960 |
| 510 | 7. | Issac A, Stephen S, Jacob J, VR V, Radhakrishnan RV, Krishnan N, et al. The Pandemic |
| 511 | | League of COVID-19: Korea Versus the United States, With Lessons for the Entire World. |
| 512 | | J Prev Med Pub Health. 2020 Jul;53(4):228–32. |
| 513 | 8. | World Organisation for Animal Health. Veterinary Laboratory Support to the Public Health |
| 514 | | Response [Internet]. 2020 [cited 2023 Mar 14]. Available from: https://rr- |
| 515 | | americas.woah.org/en/news/veterinary-laboratory-support-to-the-public-health-response/ |
| 516 | 9. | Jerry Saliki. (American Association of Veterinary Laboratory Diagnosticians). Letter to: |
| 517 | | Undisclosed recipients. 2022 Sept 22. |
| 518 | 10. | Janet Donlin. (American Veterinary Medical Association). Letter to: Sarah Bennett and |
| 519 | | Cindy Flacks (Centers for Medicare & Medicaid Services). 2022 Sept 23. |
| 520 | 11. | Taylor LH, Latham SM, Woolhouse ME. Risk factors for human disease emergence. Philos |
| 521 | | Trans R Soc B Biol Sci. 2001 Jul 29;356(1411):983–9. |
| 522 | 12. | This veterinary lab is the linchpin in one state's coronavirus testing approach - The |
| 523 | | Washington Post [Internet]. [cited 2023 Sep 11]. Available from: |

| 524 | https://www.w | vashingtonpost | com/science | /2020/05/12/th | is-veterinary | z-lab-is-linchi | oin-one- |
|-----|-------------------|----------------|-------------|----------------|---------------|-----------------|----------|
| 541 | 11000.// ** ** ** | asingtonpost | | /2020/00/12/11 | 15 votorinur | i ido is inten | Jin one |

- 525 states-covid-19-testing-approach/
- 526 13. Cima G. Animal health laboratories aid testing for COVID-19 in people [Internet]. American
- 527 Veterinary Medical Association. [cited 2023 Mar 14]. Available from:
- 528 https://www.avma.org/javma-news/2020-06-01/animal-health-laboratories-aid-testing-
- 529 covid-19-people
- 530 14. Nolen RS. Veterinary labs continue to support COVID-19 testing [Internet]. American
- 531 Veterinary Medical Association. [cited 2023 Mar 14]. Available from:
- https://www.avma.org/javma-news/2020-07-01/veterinary-labs-continue-support-covid-19testing
- 534 15. USDA APHIS | Cases of SARS-CoV-2 in Animals in the United States [Internet]. [cited
- 535 2023 Sep 11]. Available from: https://www.aphis.usda.gov/aphis/dashboards/tableau/sars536 dashboard
- 537 16. Laverack M, Tallmadge RL, Venugopalan R, Sheehan D, Ross S, Rustamov R, et al. The
- 538 Cornell COVID-19 Testing Laboratory: A Model to High-Capacity Testing Hubs for
- 539 Infectious Disease Emergency Response and Preparedness. Viruses. 2023 Jul;15(7):1555.
- 540 17. Ramanujan K. Cornell teams work tirelessly to limit COVID spread [Internet]. Cornell
- 541 Chronicle. [cited 2023 Mar 14]. Available from:
- 542 https://news.cornell.edu/stories/2020/10/cornell-teams-work-tirelessly-limit-covid-spread

| 543 | 18. Frazier PI, Cashore JM, Duan N, Henderson SG, Janmohamed A, Liu B, et al. Modeling for |
|-----|---|
| 544 | COVID-19 college reopening decisions: Cornell, a case study. Proc Natl Acad Sci U S A. |
| 545 | 2022 Jan 11;119(2):e2112532119. |
| 546 | 19. U Of I Lab Working To Reduce Time To Get Results Of Saliva COVID-19 Tests [Internet]. |
| 547 | NPR Illinois. 2020 [cited 2023 Sep 11]. Available from: |
| 548 | https://www.nprillinois.org/illinois/2020-09-03/u-of-i-lab-working-to-reduce-time-to-get- |
| 549 | results-of-saliva-covid-19-tests |
| | |
| 550 | 20. Health C for D and R. FAQs on Testing for SARS-CoV-2. FDA [Internet]. 2023 Aug 16 |
| 551 | [cited 2023 Sep 12]; Available from: https://www.fda.gov/medical-devices/coronavirus- |
| 552 | covid-19-and-medical-devices/faqs-testing-sars-cov-2 |
| 552 | |
| 222 | 21. 42 CFR 493.1443 Standard; Laboratory director qualifications. [Internet]. [cited 2023 Sep |
| 554 | 11]. Available from: https://www.ecfr.gov/current/title-42/part-493/section-493.1443 |
| 555 | 22. Tewari D, Zeman DH. 2020, a year to remember: AAVLD perspective. J Vet Diagn Investig |
| 556 | Off Publ Am Assoc Vet Lab Diagn Inc. 2021 May;33(3):393–5. |
| 557 | 23. Weiss RA, Sankaran N. Emergence of epidemic diseases: zoonoses and other origins. Fac |
| 558 | Rev. 2022 Jan 18:11:2 |
| | |
| 559 | Supporting Information |
| 560 | S1 File. Survey Distributed to Veterinary Diagnostic Laboratories. Following formal survey |

- 561 approval by the American Association of Veterinary Medical Colleges, this online cross-
- 562 sectional Qualtrics survey was distributed to American Association of Veterinary Medical

- 563 Colleges and the National Animal Health Laboratory Network member laboratories in the United
- 564 States.
- 565 **S2 File. Interview Questions.** To learn more about the specific elements of a laboratory's
- 566 response, a convenience sample of survey respondents were asked to participate in a semi-
- 567 structured interview.



Created with Datawrapper





Figure



Figure